OMGA 250117 5.00P (OMGA250117P5000) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayClose Jan 17 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Jan 1 15:20

🟢 Watchlist JANUARY 2,2025 -Thursday

HAPPY NEW YEAR 😉
NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 CH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, some stocks may get pumped WITHOUT any catalyst
8. It’s 2025, those newbies need to read and educate themselves on stocks. ...

Trytosaveabit

Dec 31 16:50

A bit from new 8K just filed!

$Omega Therapeutics (OMGA.US)$ Item 8.01. Other Events.
On December 29, 2024, the Company received a non-binding proposal (the “Proposal”) from Mirai Bio, Inc., an affiliate of Flagship Pioneering Fund VII, L.P (“Mirai”), to modify the terms of the Company’s Research Collaboration Agreement with Novo Nordisk A/S and Pioneering Medicines 08, Inc., dated as of December 31, 2023 (the “Collaboration Agreement”).
Under the terms of the Proposal, Mirai would acquire all of ...

104294857

Nov 26, 2024 06:40

$Omega Therapeutics (OMGA.US)$ about to fly 🚀 take note guyss

Jaguar8

Nov 20, 2024 05:46

NEWS

$Omega Therapeutics (OMGA.US)$
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer
Ampersand's AND™ Platform will be used to identify programmed biologics for the
treatment of obesity-related targets
Montai's CONECTA™ AI platform will be used to identify small molecules directed to a
potential Non-Small Cell Lung Cancer-related target
Collaborations will leverage Pfizer's deep expertise in early di...

Jaguar8

Nov 14, 2024 15:06

NEWS

$Omega Therapeutics (OMGA.US)$
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
Positive
Phase 1 MYCHELANGELO trial showed 50% disease control rate in HCC patients
Reduced net loss to $16.4M in Q3 2024 from $22.2M in Q3 2023
R&D expenses decreased by $3.7M compared to Q3 2023
G&A expenses reduced by $1.0M compared to Q3 2023
Ongoing collaboration with Novo Nor...